基于Oncomine和TCGA数据库分析SLC2A1基因在肺腺癌中的表达意义

目的阐明SLC2A1基因在肺腺癌中的表达及临床意义。方法通过检索Oncomine和TCGA等生物信息数据库中有关SLC2A1的信息,并对所获取的数据资料挖掘并进行二次分析,对SLC2A1在肺腺癌中的作用进行荟萃分析。结果 Oncomine数据库中共收集了448项不同类型SLC2A1的研究结果,关于在肿瘤与对照组织中SLC2A1表达有统计学差异的结果有47项,其中SLC2A1表达增高的有43项,表达降低的有4项。肺腺癌中高表达的研究有8项、低表达的有0项。共有8项研究数据集涉及SLC2A1在肺腺癌组织和正常组织中的表达,包括786例样本。在数据库中综合比较这8项研究成果,发现与对照组相比,SLC2A1在肺腺癌中的表达高于正常组织(P0.05)。另外,免疫组织化学显示SLC2A1在肺腺癌组织中表达较强或中等,而在正常组织中表达较弱或呈阴性。TCGA数据库中挖掘的结果也同样显示高表达SLC2A1的患者总体死亡率较高,低表达SLC2A1的患者预后较好(P0.05)。结论基于公共数据库中肿瘤相关的基因信息,提示SLC2A1的m RNA水平在肺腺癌组织中呈现高表达,并与肺腺癌预后相关,其有望成为肺腺癌药物治疗的重要治疗靶点。

Expression and clinical significance of SLC2A1 in lung adenocarcinoma: Analysis based on the data-mining of public database

Objective To explore the expression of SLC2A1 and its clinical significance in lung adenocarcinoma. Methods Data about SLC2A1 were retrieved from the Oncomine and TCGA database, then the role of SLC2A1 in lung adenocarcinoma was mined and analyzed. Results Totally 448 different types of cancer studies about the expression of SLC2A1 were identified in the Oncomine database. The SLC2A1 expression was statistically significant in 47 of the studies, over-expressed in 43 (8 in lung adenocarcinoma) and under-expressed in the other 4 (0 in lung adenocarcinoma). Eight datasets from eight different studies with 786 samples, addressed the expression of SLC2A1 in lung adenocarcinoma and normal tissues. The expression of SLC2A1 was significantly higher in the cancer than in the normal tissues (P<0.05). In addition, immunohistochemistry showed that SLC2A1 was highly or moderately expressed in lung adenocarcinoma tissues, while it was weakly or negatively expressed in normal tissues. Furthermore, through mining and analyzing the data from TCGA database, the prognostic data showed a higher total mortality rate in the patients with higher SLC2A1 expression than in those with a lower expression (P<0.05). Conclusion SLC2A1 is over-expressed in lung adenocarcinoma, and its expression is associated with the prognosis of lung adenocarcinoma, which may be used as an important target of medication for lung adenocarcinoma in the clinic.